Přehled o publikaci
2024
Cyanotoxin cylindrospermopsin disrupts lipid homeostasis and metabolism in a 3D in vitro model of the human liver
ROY CHOWDHURY, Riju, Marina FELIPE GROSSO, Darshak Chandulal GADARA, Zdeněk SPÁČIL, Veronika VIDOVÁ et. al.Basic information
Original name
Cyanotoxin cylindrospermopsin disrupts lipid homeostasis and metabolism in a 3D in vitro model of the human liver
Authors
ROY CHOWDHURY, Riju (356 India, belonging to the institution), Marina FELIPE GROSSO (380 Italy, belonging to the institution), Darshak Chandulal GADARA (356 India, belonging to the institution), Zdeněk SPÁČIL (203 Czech Republic, belonging to the institution), Veronika VIDOVÁ (203 Czech Republic, belonging to the institution), Iva SOVADINOVÁ (203 Czech Republic, belonging to the institution) and Pavel BABICA (203 Czech Republic, guarantor, belonging to the institution)
Edition
Chemico-Biological Interactions, Clare, Elsevier Ireland Ltd. 2024, 0009-2797
Other information
Language
English
Type of outcome
Article in a journal
Country of publisher
Ireland
Confidentiality degree
is not subject to a state or trade secret
References:
RIV identification code
RIV/00216224:14310/24:00136669
Organization
Přírodovědecká fakulta – Repository – Repository
UT WoS
001247294100001
EID Scopus
2-s2.0-85194163267
Keywords in English
Harmful cyanobacterial blooms; Hepatospheroids; LC-MS-Based lipid profiling; Non-alcoholic fatty liver disease; NAFLD; Metabolic dysfunction-associated fatty liver; disease; MAFLD
Links
GA19-19143S, research and development project. LM2023050, research and development project. 825712, interní kód Repo. 857560, interní kód Repo. ELIXIR CZ III, large research infrastructures. RECETOX RI II, large research infrastructures.
Changed: 28/5/2025 00:50, RNDr. Daniel Jakubík
Abstract
V originále
Cylindrospermopsin, a potent hepatotoxin produced by harmful cyanobacterial blooms, poses environmental and human health concerns. We used a 3D human liver in vitro model based on spheroids of HepG2 cells, in combination with molecular and biochemical assays, automated imaging, targeted LC-MS-based proteomics, and lipidomics, to explore cylindrospermopsin effects on lipid metabolism and the processes implicated in hepatic steatosis. Cylindrospermopsin (1 mu M, 48 h) did not significantly affect cell viability but partially reduced albumin secretion. However, it increased neutral lipid accumulation in HepG2 spheroids while decreasing phospholipid levels. Simultaneously, cylindrospermopsin upregulated genes for lipogenesis regulation (SREBF1) and triacylglycerol synthesis (DGAT1/2) and downregulated genes for fatty acid synthesis (ACLY, ACCA, FASN, SCD1). Fatty acid uptake, oxidation, and lipid efflux genes were not significantly affected. Targeted proteomics revealed increased levels of perilipin 2 (adipophilin), a major hepatocyte lipid droplet-associated protein. Lipid profiling quantified 246 lipid species in the spheroids, with 28 significantly enriched and 15 downregulated by cylindrospermopsin. Upregulated species included neutral lipids, sphingolipids (e.g., ceramides and dihexosylceramides), and some glycerophospholipids (phosphatidylethanolamines, phosphatidylserines), while phosphatidylcholines and phosphatidylinositols were mostly reduced. It suggests that cylindrospermopsin exposures might contribute to developing and progressing towards hepatic steatosis or metabolic dysfunctionassociated steatotic liver disease (MASLD).